BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant Environment
BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
Comprised of a patient mobile application that integrates with digital devices (IoT) and a clinician dashboard integrated into the Electronic Health Record (EHR), the AstraZeneca AMAZE™ Disease Management Platform built on the BrightInsight Platform, captures pertinent clinical information through connected devices, supports quality of life measures and Patient-Reported Outcomes (PROs), and provides a direct communication channel between the patient and their care team. From project kick-off to go-live in less than 12 months, BrightInsight’s proven platform and pre-built functionality significantly accelerated AstraZeneca’s time to market.
SAN JOSE, Calif., March 16, 2021 (GLOBE NEWSWIRE) — BrightInsight, Inc., provider of the leading global regulated digital health platform for biopharma and medtech, announced today the launch of the AstraZeneca AMAZE™ Disease Management Platform built on the BrightInsight™ Platform. The AstraZeneca AMAZE™ Platform aims to improve outcomes in patients by providing an end-to-end digital solution closing the gap between patient and providers across multiple chronic conditions including asthma, COPD, heart failure, chronic kidney disease, and diabetes.
The Centers for Disease Control and Prevention report that 6 in 10 adults in the U.S. have a chronic disease, and 4 in 10 have two or more. Chronic diseases in the U.S. are the leading causes of death and disability and the leading drivers of the nation’s $3.8 Trillion annual health care costs. Despite having effective drugs and therapies in the market today and an increased awareness of the importance of health and well-being, the rate of chronic disease continues to rise. The options for remote-monitoring solutions are numerous, however very few offer a unified patient experience across multiple conditions and are integrated into the clinical workflow, which are critical drivers to adoption and scale.
Comprised of a patient mobile application that integrates with digital devices (IoT) and a clinician dashboard integrated into the Electronic Health Record, the AstraZeneca AMAZE Platform aims to tackle these challenges by bridging the gap between patients and their healthcare providers and delivering valuable insights at the point of care to improve management of this complex patient population. From project kick off to commercialization in less than a year, the BrightInsight Platform accelerated time to market for the AstraZeneca Disease Management Platform through its pre-built functionality, including Electronic Health Record (EHR) integration with leading hospitals and health systems within the U.S. BrightInsight also reduces risk for AstraZeneca as it supports compliance with privacy, security and regulatory requirements for its customer’s solutions built on the BrightInsight Platform.
“We announced our global digital health partnership with AstraZeneca in March 2020, and could not be more pleased to see the launch of a transformational digital health product from AstraZeneca on our BrightInsight Platform,” said Kal Patel, MD, CEO & Co-Founder, BrightInsight. “This specific collaboration is a fantastic proof point of BrightInsight’s cross-therapeutic, open ecosystem approach, and in our ability to successfully execute and launch real-world digital health products on behalf of our customers.”
“Digital can play a huge role in improving patient engagement and therapy adherence for their own chronic diseases, as well as providing their physicians better insights to deliver more personalized care in real-time,” said Karan Arora, Chief Commercial Digital Officer and Global Vice President, AstraZeneca. “By leveraging the compliant BrightInsight Platform and its pre-built integrations into the clinician workflow, we were able to accelerate our time to market and focus on what truly matters – improving patient outcomes and creating care delivery efficiencies, at scale.”
The AMAZE Disease Management Platform launched on the BrightInsight Platform in October 2020. AstraZeneca will continue to expand across therapeutic areas and regions in 2021.
ABOUT BRIGHTINSIGHT, INC.
BrightInsight provides the leading global regulated digital health platform for biopharma and medtech. When speed matters, we help leading companies accelerate time to market for regulated digital health offerings including apps, algorithms, medical devices, combination products, or Software as a Medical Device (SaMD) across therapeutic areas. BrightInsight replaces the need for lengthy and complicated ‘built from scratch’ implementations and instead offers a pre-built and proven platform developed under a Quality Management System to support global security, privacy, and regulatory requirements. When you build your digital health products on the BrightInsight Platform, you are future-proofing your highest-value offerings from a compliance standpoint and unlocking scaling opportunities that simply aren’t available without our agile approach. For more information, visit BrightInsight’s website, Blog, Twitter and LinkedIn pages.
Media & Press
Jamie Burgess
VP, Marketing, BrightInsight
1.669.268.2838
jamie.burgess@brightinsight.com
Helen Shik
BrightInsight PR Firm
Shik Communications LLC
1.617.510.4373
Shik.helen10@gmail.com
Copyright © 2021 BrightInsight, Inc. BrightInsight and the BrightInsight logo are trademarks of BrightInsight, Inc. Other trademarks are the trademarks of their owners.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/80cb794e-e8c9-4dd5-98e9-0a174f87b6b2
